Large Cap Healthcare Stocks Declining Over 10% in 2011

Wall St. Watchdog uncovers large cap companies in the Healthcare sector whose shares have declined by more than 10% year-to-date.  The minimum market capitalization is $1 billion.

  • Edwards Lifesciences Corp (NYSE:EW): This company’s stock has declined by -11.74% year-to-date, and it recently traded at $71.35. Its market capitalization is $8,182,354,000. About the company: Edwards Lifesciences Corporation designs, develops, manufactures, and markets products and services to treat late-stage cardiovascular disease. The Company’s products include tissue replacement heart valves, heart valve repair products, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals. Edwards supplies its products to customers located worldwide.
  • Life Technologies Corp. (NASDAQ:LIFE): This company’s stock has declined by -18.86% year-to-date, and it recently traded at $45.03. Its market capitalization is $8,049,825,000. About the company: Life Technologies Corporation develops biotechnology tools used by researchers. The Company offers a broad range of products and services, including systems, instruments, reagents, and custom services. Life’s portfolio of products includes technologies for capillary electrophoresis based sequencing, sequencing, mass spectrometry sample preparation, and cell culture.
  • ResMed Inc. (NYSE:RMD): This company’s stock has declined by -12.56% year-to-date, and it recently traded at $30.29. Its market capitalization is $4,631,793,000. About the company: ResMed Inc. develops, manufactures, and markets medical equipment for the treatment of sleep disordered breathing. The Company sells diagnostic and treatment devices in various countries through its subsidiaries and independent distributors. ResMed, Inc. Fourth Quarter Earnings Sneak Peek>>
  • Human Genome Sciences (NASDAQ:HGSI): This company’s stock has declined by -12.06% year-to-date, and it recently traded at $21.01. Its market capitalization is $4,005,956,000. About the company: Human Genome Sciences, Inc. researches and develops proprietary pharmaceutical and diagnostic products. The Company’s products predict, prevent, detect, treat, and cure disease based on the discovery of human and microbial genes.
  • Tenet Healthcare Corporation (NYSE:THC): This company’s stock has declined by -16.89% year-to-date, and it recently traded at $5.56. Its market capitalization is $3,056,590,000. About the company: Tenet Healthcare Corporation, through its subsidiaries, owns or operates general hospitals and related health care facilities serving communities in the United States. The Company operates rehabilitation hospitals, specialty hospitals, long-term care facilities, psychiatric facilities, and medical office buildings near its general hospitals, as well as ancillary health care businesses.
  • Community Health Systems (NYSE:CYH): This company’s stock has declined by -30.85% year-to-date, and it recently traded at $25.84. Its market capitalization is $2,453,958,000. About the company: Community Health Systems Inc. owns, leases, and operates hospitals in multiple states. The Hospitals services include emergency room services, general surgery, critical care, internal medicine, obstetrics and diagnostic services. Community Health also owns interests in physicians, physician practices, imaging centers, home health agencies and ambulatory surgery centers.
  • Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP): This company’s stock has declined by -17.42% year-to-date, and it recently traded at $38.78. Its market capitalization is $2,264,737,000. About the company: Salix Pharmaceuticals, Ltd. develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. The Company markets its products to gastroenterologists in the U.S. through its own specialty sales force.
  • Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX): This company’s stock has declined by -10.55% year-to-date, and it recently traded at $32.98. Its market capitalization is $2,089,461,000. About the company: Onyx Pharmaceuticals, Inc. discovers and develops novel therapeutics based upon the genetics of human disease, with an emphasis on cancer. The Company focuses on defining the function of certain mutated genes which are known to cause cancer, and on developing therapies to reverse the effects of the mutation or to kill the cancer cell.
  • Theravance, Inc. (NASDAQ:THRX): This company’s stock has declined by -14.72% year-to-date, and it recently traded at $21.38. Its market capitalization is $1,797,958,000. About the company: Theravance, Inc. is a biopharmaceutical company that discovers, develops, and markets small molecule medicines for unmet medical needs across a number of therapeutic areas including respiratory disease, bacterial infections, and gastrointestinal disorders.
  • Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN): This company’s stock has declined by -19.03% year-to-date, and it recently traded at $11.91. Its market capitalization is $1,736,967,000. About the company: Amylin Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for diabetes and obesity. The Company’s marketed products include treatments for adults with type 1 and type 2 diabetes.

(Note: Selected financial data are sourced from screener.co.  All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter >>